What is claimed is:

1. A compound of the formula I, or a salt, solvate, or a physiologically functional derivative thereof

5

Ι

in which

R2 is a radical of the formula

10

in which

15
$$n = 1 - 2;$$

w = 0 - 2;

R3 and R4 are independently hydrogen, hydroxy, -OR6, halogen, $-SO_2NH_2$, -OH, $-C_{1-6alkyl}$, -(C=O)-OEt, $-NH(C=O)-CH_3$, or a radical of the formula

$$\bigcap_{N}$$
 ; and

R5 is $-NH_2$, hydrogen, -OR6, -N(R6)(R7), or a radical of the formula

5

R1 is a radical of the formula

, or
$$H_2N$$

R8 is a radical of the formula

R9 is $-NH(C=O)CH_3$, $-SO_2NH_2$, $-SO_2N(R6)(R7)$; and

R6 and R7 are independently C_{1.6}alkyl.

5

2. A compound of claim 1 in which R1 is a radical of the formula

3. A compound of claim 2 in which R1 is a radical of the formula

4. A compound of claim 3 in which R8 is 2-thienyl.

5

5. A method of inhibiting hYAK3 in a mammal; comprising, administering to the mammal a therapeutically effective amount of a compound of formula I, or a salt, solvate, or a physiologically functional derivative thereof

10

Ι

in which

R2 is a radical of the formula

in which

n = 1 - 2;

5 w = 0 - 2;

R3 and R4 are independently hydrogen, hydroxy, \cdot OR6, halogen, \cdot SO₂NH₂, \cdot OH, \cdot C₁₋₆alkyl, \cdot (C=O) \cdot OEt, \cdot NH(C=O) \cdot CH₃, or a radical of the formula

$$\bigcap_{O}^{N}$$
; and

10

R5 is -NH₂, hydrogen, -OR6, -N(R6)(R7), or a radical of the formula

R1 is a radical of the formula

, or
$$H_2N$$
 , or H_2N , $H_$

R8 is a radical of the formula

R9 is -NH(C=O)CH3, -SO2NH2, -SO2N(R6)(R7); and

R6 and R7 are independently $C_{1\text{-}6}$ alkyl.

6. A method of treating or preventing diseases of the erythroid and hematopoietic systems, caused by the hYAK3 imbalance or inappropriate activity; comprising, administering to a mammal a therapeutically effective amount of a compound formula

5 I, or a salt, solvate, or a physiologically functional derivative thereof

Ι

in which

10 R2 is a radical of the formula

in which

15 n = 1 - 2;w = 0 - 2;

R3 and R4 are independently hydrogen, hydroxy, \cdot OR6, halogen, \cdot SO₂NH₂, \cdot OH, \cdot C1-6alkyl, \cdot (C=O) \cdot OEt, \cdot NH(C=O) \cdot CH₃, or a radical of the formula

$$\bigcup_{O}^{N}$$
; and

R5 is $-NH_2$, hydrogen, -OR6, -N(R6)(R7), or a radical of the formula

5 R1 is a radical of the formula

, or
$$H_2N$$
 , or $R8$

R8 is a radical of the formula

R9 is $-NH(C=O)CH_3$, $-SO_2NH_2$, $-SO_2N(R6)(R7)$; and

R6 and R7 are independently C1 calkyl.

- 7. A method of claim 6 in which diseases of the erythroid and hematopoietic systems are selected from the group consisting of anemia, aplastic anemia, myelodysplastic syndrome, myelosuppression, and cytopenia.
- 8. A method of treating or preventing diseases selected from the group consisting of anemia, aplastic anemia, myelodysplastic syndrome, myelosuppression, and cytopenia; comprising, administering to a mammal a therapeutically effective amount of a compound formula I, or a salt, solvate, or a physiologically functional derivative thereof

in which

R2 is a radical of the formula


5

in which

$$n = 1 - 2;$$

10
$$w = 0 - 2;$$

R3 and R4 are independently hydrogen, hydroxy, \cdot OR6, halogen, \cdot SO₂NH₂, \cdot OH, \cdot C_{1-6alkyl}, \cdot (C=O) \cdot OEt, \cdot NH(C=O) \cdot CH₃, or a radical of the formula



R5 is -NH2, hydrogen, -OR6, -N(R6)(R7), or a radical of the formula

R1 is a radical of the formula

, or
$$H_2N$$
 , or $R8$

R8 is a radical of the formula

R9 is -NH(C=O)CH3, -SO2NH2, -SO2N(R6)(R7); and

R6 and R7 are independently C₁₋₆alkyl.

5

9. A pharmaceutical composition including a therapeutically effective amount of a compound formula I, or a salt, solvate, or a physiologically functional derivative thereof, and one or more pharmaceutically acceptable carriers, diluents and excipients

10

I

, or

in which

R2 is a radical of the formula

$$N$$
 ; and

15 in which

n = 1 - 2;

w = 0 - 2;

R3 and R4 are independently hydrogen, hydroxy, -OR6, halogen, -SO₂NH₂, -OH, -C₁₋₆alkyl, -(C=O)-OEt, -NH(C=O)-CH₃, or a radical of the formula

$$\bigcap_{O}^{N}$$
; and

5

R5 is -NH2, hydrogen, -OR6, -N(R6)(R7), or a radical of the formula

R1 is a radical of the formula

, or
$$H_2N$$
 , or H_2N , H_2N

10

· R8 is a radical of the formula

R9 is -NH(C=O)CH₃, -SO₂NH₂, -SO₂N(R6)(R7); and

R6 and R7 are independently C1-calkyl.

- 10. A compound selected from the group consisting of:
- 2-(2-Amino-ethylamino)-6-quinolin-6-yl-3H-pyrimidin-4-one;
- 2-(2-Dimethylamino-ethylamino)-6-quinolin-6-yl-1H-pyrimidin-4-one;
- 10 2-(3-Methoxy-benzylamino)-6-quinolin-6-yl-1H-pyrimidin-4-one;
 - 2-{[2,6-Bis(methyloxy)phenyl]amino}-6-(6-quinolinyl)-4(1H)-pyrimidinone;
 - N-(5-{2-[(2-Chlorophenyl)amino]-6-oxo-1,6-dihydro-4-pyrimidinyl}-1H-benzimidazol-2-y l)-2-thiophenecarboxamide;

N-{5-[6-Oxo-2-(4-pyridinylamino)-1,6-dihydro-4-pyrimidinyl]-1H-benzimidazol-2-yl}-2-t hiophenecarboxamide;

N-[5-(2-{[3-(Aminosulfonyl)phenyl]amino}-6-oxo-1,6-dihydro-4-pyrimidinyl)-1H-benzim idazol-2-yl]-2-thiophenecarboxamide;

5 N-{5-[6-Oxo-2-(phenylamino)-1,6-dihydro-4-pyrimidinyl]-1H-benzimidazol-2-yl}-2-thiop henecarboxamide;

N-(5-{2-[(3-Hydroxyphenyl)amino]-6-oxo-1,6-dihydro-4-pyrimidinyl}-1H-benzimidazol-2-yl)-2-thiophenecarboxamide;

N-{5-[2-(1H-Indazol-6-ylamino)-6-oxo-1,6-dihydro-4-pyrimidinyl]-1H-benzimidazol-2-yl}-2-thiophenecarboxamide;

N-[5-(2-{[4-(Methyloxy)phenyl]amino}-6-oxo-1,6-dihydro-4-pyrimidinyl)-1H-benzimidaz ol-2-yl]-2-thiophenecarboxamide;

N-[5-(2-{[2-(Methyloxy)ethyl]amino}-6-oxo-1,6-dihydro-4-pyrimidinyl)-1H-benzimidazol -2-yl]-2-thiophenecarboxamide;

15

20

25

 $N-[5-(2-\{[2-(Methyloxy)phenyl]amino\}-6-oxo-1,6-dihydro-4-pyrimidinyl)-1H-benzimidaz\\ ol-2-yl]-2-thiophenecarboxamide;$

N-[5-(2-{[3-(Methyloxy)phenyl]amino}-6-oxo-1,6-dihydro-4-pyrimidinyl)-1H-benzimidaz ol-2-yl]-2-thiophenecarboxamide;

 $N-[5-(2-\{[3-(Dimethylamino)propyl]amino\}-6-oxo-1,6-dihydro-4-pyrimidinyl)-1H-benzi\\ midazol-2-yl]-2-thiophenecarboxamide;$

N-[5-(2-{[2-(2,4-Dichlorophenyl)ethyl]amino}-6-oxo-1,6-dihydro-4-pyrimidinyl)-1H-benz imidazol-2-yl]-2-thiophenecarboxamide;

N-[5-(2-{[2-(4-Morpholinyl)phenyl]amino}-6-oxo-1,6-dihydro-4-pyrimidinyl)-1H-benzimi dazol-2-yl]-2-thiophenecarboxamide;

- N-(5-{2-[(2-Fluorophenyl)amino]-6-oxo-1,6-dihydro-4-pyrimidinyl}-1H-benzimidazol-2-y l)-2-thiophenecarboxamide;
- 5 N-(5-{2-[(2,5-Dichlorophenyl)amino]-6-oxo-1,6-dihydro-4-pyrimidinyl}-1H-benzimidazol -2-yl)-2-thiophenecarboxamide;
 - N-{5-[2-(Ethylamino)-6-oxo-1,6-dihydro-4-pyrimidinyl]-1H-benzimidazol-2-yl}-2-thioph enecarboxamide;
 - N-(5-{2-[(2-Methylphenyl)amino]-6-oxo-1,6-dihydro-4-pyrimidinyl}-1H-benzimidazol-2-yl)-2-thiophenecarboxamide;
 - N-[5-(6-Oxo-2-{[3-(2-oxo-1-pyrrolidinyl)propyl]amino}-1,6-dihydro-4-pyrimidinyl)-1H-be nzimidazol-2-yl]-2-thiophenecarboxamide;
 - N-(5-{2-[(1,3-Dioxolan-2-ylmethyl)amino]-6-oxo-1,6-dihydro-4-pyrimidinyl}-1H-benzimi dazol-2-yl)-2-thiophenecarboxamide;
- 3-(Acetylamino)-N-(5-{2-[(2-chlorophenyl)amino]-6-oxo-1,6-dihydro-4-pyrimidinyl}-1H-benzimidazol-2-yl)benzamide;
 - N-(5-{2-[(2-Chlorophenyl)amino]-6-oxo-1,6-dihydro-4-pyrimidinyl}-1H-benzimidazol-2-y l)cyclopropanecarboxamide;
 - 4-(Aminosulfonyl)-N-(5-{2-[(2-chlorophenyl)amino]-6-oxo-1,6-dihydro-4-pyrimidinyl}-1
- 20 H-benzimidazol-2-yl)benzamide;

- N-(5-{2-[(2-Chlorophenyl)amino]-6-oxo-1,6-dihydro-4-pyrimidinyl}-1H-benzimidazol-2-y l)-4-[(dipropylamino)sulfonyl]benzamide;
- N-(5-{2-[(2-Chlorophenyl)amino]-6-oxo-1,6-dihydro-4-pyrimidinyl}-1H-benzimidazol-2-y l)-1H-imidazole-4-carboxamide;
- N-(5-{2-[(2-Chlorophenyl)amino]-6-oxo-1,6-dihydro-4-pyrimidinyl}-1H-benzimidazol-2-y

- 1)-3,4,5-tris(methyloxy)benzamide;
- N-(5-{2-[(2-Chlorophenyl)amino]-6-oxo-1,6-dihydro-4-pyrimidinyl}-1H-benzimidazol-2-y l)-3-pyridinecarboxamide;
- $N-(5-\{2-[(2-chlorophenyl)amino]-6-oxo-1,6-dihydro-4-pyrimidinyl\}-1H-benzimidazol-2-ylawal-1-2-yla$
- 5)-2-(methyloxy)acetamide;
 - N-(5-{2-[(2-Chlorophenyl)amino]-6-oxo-1,6-dihydro-4-pyrimidinyl}-1H-benzimidazol-2-y l)-2-(4-methyl-1-piperazinyl)acetamide;
 - 4-(4-Methyl-1-piperazinyl)-N-{5-[6-oxo-2-(phenylamino)-1,6-dihydro-4-pyrimidinyl]-1H-benzimidazol-2-yl}benzamide;
- 6-(2-Amino-1H-benzimidazol-5-yl)-2-({[3-(methyloxy)phenyl]methyl}amino)-4(1H)-pyri midinone;
 - N-{5-[2-({[3-(Methyloxy)phenyl]methyl}amino)-6-oxo-1,6-dihydro-4-pyrimidinyl]-1H-be nzimidazol-2-yl}-2-thiophenecarboxamide;
 - 6-Benzo[1,3]dioxol-5-yl-2-(3-methoxy-benzylamino)-1H-pyrimidin-4-one;
- 15 6-(1,3-Benzodioxol-5-yl)-2-(1H-indazol-5-ylamino)-4(1H)-pyrimidinone;
 - $6\hbox{-}(1,3\hbox{-}Benzo diox ol\hbox{-}5\hbox{-}yl)\hbox{-}2\hbox{-}\{[3\hbox{-}(methyloxy)phenyl]amino}\}\hbox{-}4(1H)\hbox{-}pyrimid in one; }$
 - 3-{[4-(1,3-Benzodioxol-5-yl)-6-oxo-1,6-dihydro-2-pyrimidinyl]amino}benzenesulfonamide;
 - 6-(1,3-Benzodioxol-5-yl)-2-{[2-(methyloxy)phenyl]amino}-4(1H)-pyrimidinone;
- 20 2-[(2-Chlorophenyl)amino]-6-(4-pyridinyl)-4(1H)-pyrimidinone;
 - 2-(1H-Indazol-6-ylamino)-6-(4-pyridinyl)-4(1H)-pyrimidinone;
 - $3\hbox{-}\{[4\hbox{-}Oxo\hbox{-}6\hbox{-}(4\hbox{-}pyridinyl)\hbox{-}1,4\hbox{-}dihydro\hbox{-}2\hbox{-}pyrimidinyl]amino}\} benzene sulfonamide;$
 - $\hbox{$2$-{[3-(methyloxy)phenyl]amino}-6$-(4-pyridinyl)-4(1H)-pyrimidinone;}$
- $25 \qquad \hbox{$2$-(Phenylamino)-6-(4-pyridinyl)-4(1H)-pyrimidinone;}$

Ethyl 3-{[4-oxo-6-(4-pyridinyl)-1,4-dihydro-2-pyrimidinyl]amino}benzoate;

 $\hbox{$4$-{$(4$-Oxo-6-(4$-pyridinyl)-1,4$-dihydro-2-pyrimidinyl]amino}$ benzene sulfonamide;}$

6-(4-Pyridinyl)-2-(4-pyridinylamino)-4(1H)-pyrimidinone; and

N-(3-{[4-Oxo-6-(4-pyridinyl)-1,4-dihydro-2-pyrimidinyl]amino}phenyl)acetamide.